Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

SPCCT

Financiado

Cerrado

In Vivo Spectral Photon Counting CT Molecular Imaging in Cardio and Neuro Vascu...

In Vivo Spectral Photon Counting CT Molecular Imaging in Cardio and Neuro Vascular Diseases The objective of the SPCCT project is to develop and validate a widely accessible, new quantitative and analytical in vivo imaging technology combining Spectral Photon Counting CT and contrast agents, to accurately and early detec... ver más

30/06/2021

UNIVERSITE LYON 1...

6M€

Presupuesto del proyecto: 6M€

Líder del proyecto

UNIVERSITE LYON 1 CLAUDE BERNARD No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 11 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2021-06-30

PHC-11-2015: Development of new diagnostic tools...

I+D

Cerrada hace 10 años

0% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

11 Participantes

UNIVERSITE LYON 1 CLAUDE BER...

2.14M€ | Lider

LIP

229.75K€ | Participante

UNITO

535.50K€ | Participante

CLINIQUES UNIVERSITAIRES SAI...

96.72K€ | Participante

Proyectos interesantes

RETIMAGER

Medical Technol...

Applied Physics

3M€ Cerrado

BRAINSPECT

Medical Technol...

Applied Physics

71K€ Cerrado

CTQ2016-74862-P

Medical Technol...

Applied Physics

62K€ Cerrado

KOLOR SPCCT IMAGING

Medical Technol...

Applied Physics

2M€ Cerrado

SCOPE

Medical Technol...

Applied Physics

222K€ Cerrado

SEFC

Medical Technol...

Applied Physics

164K€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 66 meses Fecha Inicio: 2015-12-09
Fecha Fin: 2021-06-30

Líder del proyecto

UNIVERSITE LYON 1 CLAUDE BERNARD No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 6M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto The objective of the SPCCT project is to develop and validate a widely accessible, new quantitative and analytical in vivo imaging technology combining Spectral Photon Counting CT and contrast agents, to accurately and early detect, characterize and monitor neurovascular and cardiovascular disease. Spectral Photon Counting Computed Tomography (SPCCT) is a new imaging modality, currently in development, with a totally new type of detection chain designed to provide high count-rate capabilities while offering energy discrimination with high spatial resolution of 200µm. Based on this discrimination, SPCCT can detect and quantify accurately a large variety of atoms (including Gadolinium, Gold, Bismuth…) by using the K-edge technique. SPCCT, by a more accurate, less invasive (in comparison with IVUS and coronary angiography) and reliable evaluation of vascular inflammation will allow earlier disease diagnosis such as plaque inflammation before rupture, leading to improved clinical decisions and outcomes. This will be achievable with a high spatial resolution combined to the newly developed vascular inflammation specific contrast agent detected with high quality K-edge technique that can only be provided by a multi-spectral X-ray system. The project will therefore provide a complete tool (acquisition system and specific probes) dedicated to CV imaging. It will finally contribute to: Improved early diagnosis of atherosclerosis, prevention of acute event (MI, stroke) and personalized preventive treatment; Improved management of patient presenting with an acute CV event and clinical validation of treatment efficiency; Sustainability and harmonization of healthcare systems, as costly disorders of heart failure and stroke-related disability would be better prevented and efficiently treated; Economic growth in the EU diagnostics sector, through the development of new targeted contrast materials for SPCCT by SMEs.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores